Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

Ipsen S.A. (Euronext: IPN; ADR: IPSEY)

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. *


Period Start 2007-08-25 existent
  Group Ipsen (Group)
Product Industry pharmaceutical
Persons Person Meek, David (Ipsen 201606– CEO before Baxalta EVP + President Oncology division + Endocyte + Novartis + JnJ)
  Person 2 le Chatelier, Aymeric (Ipsen 201603 CFO)
Region Region Paris
  Country France
  Street 42 rue du Docteur Blanche
  City 75016 Paris
  Tel +33-1-443043-43
    Address record changed: 2018-07-24
Basic data Employees F: 1,001 to 5,000 (2017-02-23)
  Currency EUR
  Annual sales 1,671,100,000 (revenue, consolidated (2016) 2016-12-31)
  Profit 226,600,000 (2016-12-31)
  Cash 425,500,000 (2016-12-31)
    * Document for �About Section�: Ipsen S.A.. (3/1/16). "Press Release: Ipsen’s 2015 Results and 2016 Financial Objectives". Paris.
Record changed: 2019-06-21


Picture [LSA] – The Business Web Portal 650x89px

More documents for Ipsen (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top